Plus   Neg

Dechra Pharma Acquires Worldwide Rights To Mirataz - Quick Facts

Dechra Pharmaceuticals plc (DPH.L) has agreed to acquire the worldwide rights to the Mirataz product portfolio from Kindred Biosciences Incorporated for a total consideration of 35.0 million pounds, and a royalty on future sales. Mirataz is the only FDA and EMA approved transdermal medication for the management of weight loss in cats.

Mirataz was launched in July 2018 and is currently only marketed in the USA. It has recently been approved in the EU for bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

Dechra Pharma expects the acquisition to be earnings enhancing for the fiscal year ending 30 June 2021, assuming completion before the end of June 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT